PDS Biotechnology Corporation (PDSB)

Strong Phase 2 Survival Data, But Stock Sells Off Anyway


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
October 4, 2023
Report ID: 26136
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


PDS Biotechnology Corporation
PDS Biotechnology Corporation
Healthcare
Biotechnology
Ticker
PDSB
Current Price
$3.87 0.26%
Market Cap
$141.9M
Price Target
Refer to Report
Volume
257.6K
52wk Range
$2.53 - $6.85
Related Research Reports
7/9/2024

Midyear Review: Has PDS Turned The Corner?
Midyear Review: Has PDS Turned The Corner? (PDSB)
5/9/2024

PDS Holds KOL Event and Announces New Trial Design
PDS Holds KOL Event and Announces New Trial Design (PDSB)
3/28/2024

FY2023 Results Included Changes In Development Strategy
FY2023 Results Included Changes In Development Strategy (PDSB)
3/4/2024

Clinical Trials Should Drive PDS In 2024
Clinical Trials Should Drive PDS In 2024 (PDSB)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy